OrbiMed

Develops neuro-metabolic therapeutics for schizophrenia and ALS

AI-first clinical enablement company and developer of remote physical examination technology featuring FDA-cleared medical devices

Clinical-stage medicines targeting inflammation and regulated cell-death pathways in immune-mediated disease.

Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases

Develops interventional therapies for pulmonary hypertension and heart failure

Develops highly targeted, small molecule medicines for cancer and rare diseases

Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma.

Develops next-generation bispecific ADCs for cancer treatment

Develops minimally invasive implantable brain-machine interfaces (BMI) for neurological diseases

Develops small molecule correctors for diseases of protein misfolding

Develops and commercializes rare disease therapies using AI

Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases

AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01.